Citius Pharmaceuticals, Inc. — Income Charts
18 years of history · ending 2025-09-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+20.0% +$15K
$90K
Cost of Revenue
$75K
R&D↓-25.2% -$3M
$9M
D&A↑+69.7% +$588
$1K
Operating Income↓-63.7% -$15M
$-39M
EBITDA↓-63.7% -$15M
$-39M
Interest Expense↑+359.0% +$39K
$50K
Interest Income↓-58.0% -$152K
$110K
Other Income/Expense↓-196.3% -$445K
$-218K
Pretax Income↓-67.8% -$16M
$-39M
Tax Provision↑+85622.6% +$1M
$1M
Net Income↓-72.4% -$17M
$-40M
Operating Margin↓-18632.3pts
-37017.8%
Net Margin↓-20663.0pts
-37378.5%
Effective Tax Rate↓-2.7pts
-2.7%
Deferred Tax Assets
$224K
Deferred Tax Liabilities↑+55.9% +$3M
$8M
DTA Valuation Allowance↑+439.7% +$54M
$66M
Tax Credit Carryforwards
$5M
NOL Carryforwards↑+495.9% +$126M
$152M
ETR (Continuing Operations)↑+2.7pts
2.7%
ETR State + Local (pp)↑+14.7pts
-6.3%
ETR Foreign Differential (pp)↑+10.3pts
4.0%
Operating Lease Cost↑+12.7% +$30K
$269K
Revenue YoY Variation↓-50.0pts
0.0%
Income YoY Variation↑+41.1pts
8.3%